

DOCON TECHNOLOGIES PRIVATE LIMITED

August 13, 2026

To, National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051	To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001
To, Thyrocare Technologies Limited D37/3, TTC MIDC, Turbhe, Navi Mumbai – 400 073	

Sub: Release of Pledge on 1,75,00,000 equity Shares of Thyrocare Technologies Limited
Ref: Disclosures pursuant to Regulations 29(2), 31(2) and Regulation 31(3) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Dear Sir & Madam,

We refer to our earlier disclosures dated September 24, 2025, November 11, 2025, December 05, 2025, March 31, 2026 and April 20, 2026 made under Regulation 31 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("**SEBI SAST Regulations**"), in respect of the encumbrance created by Docon Technologies Private Limited ("**Docon**"), Promoter of Thyrocare Technologies Limited ("**the Company**" / "**Thyrocare**"), in favour of Catalyst Trusteeship Limited, acting as Debenture Trustee in connection with the secured, unlisted, Non-Convertible Debentures ("**NCDs**") issued by API Holdings Limited, the holding company of Docon.

Docon is a wholly-owned subsidiary of API Holdings Limited and is the promoter of the Company. Docon holds 9,69,69,696 equity shares, representing 60.92% of the equity share capital of the Company. The aforesaid shares were pledged in favour of Catalyst Trusteeship Limited, acting as Debenture Trustee, as security for the NCDs issued by API Holdings Limited. As on the date of this disclosure, the outstanding principal amount of the aforesaid NCDs is INR 10,500 million. The shareholding and encumbered shareholding percentages stated in this disclosures are based on the shareholding as on August 11, 2026, being the date of release of pledge.

We wish to inform you that the pledge on 1,75,00,000 equity shares of the Company has now been released by Catalyst Trusteeship Limited, acting as the Debenture Trustee on August 11, 2026.


Accordingly, pursuant to Regulations 29(2), 31(2) and 31(3) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, please find enclosed the requisite disclosures in respect of **the release of pledge on 1,75,00,000 equity shares of the Company**, held by Docon, which were pledged in favour of Catalyst Trusteeship Limited, acting as the Debenture Trustee.

The requisite disclosures are enclosed as under:

1. Disclosure under Regulation 29(2) of the SEBI (SAST) Regulations: **Annexure I**
2. Disclosure under Regulation 31(2) & (3) of the SEBI (SAST) Regulations: **Annexure II**

You are requested to take the same on record

For Docon Technologies Private Limited


Madhuri Sudhir Sarangdhar
Company Secretary



DOCON TECHNOLOGIES PRIVATE LIMITED

Annexure-II

Format for disclosure by the Promoter(s) to the stock exchanges and to the Target Company for encumbrance of shares / invocation of encumbrance/ release of encumbrance, in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)					Thyrocare Technologies Limited (“Thyrocare”)								
Names of the stock exchanges where the shares of the target company are listed					1. BSE Limited 2. National Stock Exchange of India Limited								
Date of reporting					August 13, 2026								
Name of the promoter or PAC on whose shares encumbrance has been created/released/invoked					Promoter: Docon Technologies Private Limited PAC: API Holdings Limited								
Details of the creation of encumbrance*													
Name of the promoter(s) or PACs with him*	Promoter holding in the target company (1)		Promoter holding already encumbered (2)		Details of events pertaining to encumbrance (3)							Post event holding of Encumbered shares {creation- [(2)+(3)] / release [(2)-(3)] / invocation [(1)-(3)]}	
	Number	% of total share capital	Number	% of total share capital	Type of event {creation / Release / invocation}	Date of creation / release- invocation of encumbrance	Type of encumbrance (pledge/line/ non-disposal-undertaking/ others)	Reasons for encumbrance **	Number	% of share capital	Name of the entity in whose favor shares Encumbered ***	Number	% of total share capital
Docon Technologies Private Limited (“Docon”)	9,69,69,696	60.92	9,69,69,696	60.92	Release of pledge	August 11, 2026	Release of pledge on 1,75,00,000 equity shares of Thyrocare Technologies Limited held by	The shares were pledged as security for the NCDs issued by API Holdings Limited. The pledge over 1,75,00,000 equity shares was released by Catalyst Trusteeship Limited, acting as	Release of pledge on 1,75,00,000 equity shares of Thyrocare Technologi	10.99	Earlier, the entire shareholding of Docon in Thyrocare, comprising 9,69,69,696 equity shares, was pledged in favour of Catalyst Trusteeship Limited, acting as the Debenture Trustee, as security for the Non-Convertible Debentures issued by API Holdings Limited. Out of the aforesaid pledged shares, the	7,94,69,696	49.93

DOCON TECHNOLOGIES PRIVATE LIMITED

							Docon Technologies Private Limited (Promoter of Thyrocare Technologies Limited), which had been pledged in favour of Catalyst Trusteeship Limited in connection with the existing Non-Convertible Debentures ("NCDs") issued by API Holdings Limited.	Debenture Trustee.	es Limited held by Docon		pledge over 1,75,00,000 equity shares has now been released. The aggregate outstanding principal amount of the NCDs is INR 10,500 million (Indian Rupees Ten Thousand Five Hundred Million only). Details of outstanding principal amount of NCDs are as under: <table><tr><th>Sr</th><th>Name of NCDs Holder</th><th>Amount (INR in Mn)</th></tr><tr><td>1</td><td>Poonawalla Fincorp Limited</td><td>918.75</td></tr><tr><td>2</td><td>360 One Income Opportunities Fund - Series 7</td><td>131.25</td></tr><tr><td>3</td><td>Bagla Industries Private Limited</td><td>21.00</td></tr><tr><td>4</td><td>Tata Capital Limited</td><td>2,843.75</td></tr><tr><td>5</td><td>Ganesh Polychem Ltd</td><td>43.75</td></tr><tr><td>6</td><td>360 One Prime Limited</td><td>4,870.25</td></tr><tr><td>7</td><td>Advik Hi Tech Private Limited</td><td>29.75</td></tr><tr><td>8</td><td>Micro Labs Limited</td><td>59.50</td></tr><tr><td>9</td><td>Sak Industries Private Ltd</td><td>151.38</td></tr><tr><td>10</td><td>Ban Labs Private Limited</td><td>55.13</td></tr><tr><td>11</td><td>Lake Chemicals P Ltd</td><td>29.75</td></tr><tr><td>12</td><td>Sonnet Trade and Investments Pvt Ltd</td><td>9.63</td></tr><tr><td>13</td><td>Vara Future LLP</td><td>29.75</td></tr></table>	Sr	Name of NCDs Holder	Amount (INR in Mn)	1	Poonawalla Fincorp Limited	918.75	2	360 One Income Opportunities Fund - Series 7	131.25	3	Bagla Industries Private Limited	21.00	4	Tata Capital Limited	2,843.75	5	Ganesh Polychem Ltd	43.75	6	360 One Prime Limited	4,870.25	7	Advik Hi Tech Private Limited	29.75	8	Micro Labs Limited	59.50	9	Sak Industries Private Ltd	151.38	10	Ban Labs Private Limited	55.13	11	Lake Chemicals P Ltd	29.75	12	Sonnet Trade and Investments Pvt Ltd	9.63	13	Vara Future LLP	29.75		
Sr	Name of NCDs Holder	Amount (INR in Mn)																																																					
1	Poonawalla Fincorp Limited	918.75																																																					
2	360 One Income Opportunities Fund - Series 7	131.25																																																					
3	Bagla Industries Private Limited	21.00																																																					
4	Tata Capital Limited	2,843.75																																																					
5	Ganesh Polychem Ltd	43.75																																																					
6	360 One Prime Limited	4,870.25																																																					
7	Advik Hi Tech Private Limited	29.75																																																					
8	Micro Labs Limited	59.50																																																					
9	Sak Industries Private Ltd	151.38																																																					
10	Ban Labs Private Limited	55.13																																																					
11	Lake Chemicals P Ltd	29.75																																																					
12	Sonnet Trade and Investments Pvt Ltd	9.63																																																					
13	Vara Future LLP	29.75																																																					

DOCON TECHNOLOGIES PRIVATE LIMITED

												14	Moorjani Ventures Private Limited	29.75		
												15	Medley Pharmaceuticals Limited	29.75		
												16	Bennett Coleman and Company Limited	437.50		
												17	Urmila Behera	12.25		
												18	Warmond Fiduciary Services Limited	12.25		
												19	Warmond Fiduciary Services Limited	22.75		
												20	Warmond Fiduciary Services Limited	22.75		
												21	Warmond Fiduciary Services Limited	5.25		
												22	Mvs Ventures Private Limited	58.62		
												23	Alkram Venture Private Limited	58.62		
												24	Warmond Fiduciary Services Limited	17.50		
												25	Warmond Fiduciary Services Limited	35.00		
												26	Warmond Fiduciary Services Limited	17.50		
												27	Warmond Fiduciary Services Limited	12.25		
												28	Rajendrakumar Shivkishan Agrawal	87.50		
												29	Harjeet Kohli	26.25		
												30	Pitre Business Ventures LLP	29.75		

DOCON TECHNOLOGIES PRIVATE LIMITED

												31	Dayanidhi Maran	59.50		
												32	JPM Merchandise Agencies Limited	17.50		
												33	J Kumar Infra projects Limited	314.12		
													Total	10,500.00		

For and on behalf of Docon Technologies Private Limited


Madhuri Sudhir Sarangdhar
Company Secretary
Date: August 13, 2026



(**) The names of all the promoters, their shareholding in the target company and their pledged shareholding as on the reporting date should appear in the table irrespective of whether they are reporting on the date of event or not.

(*) Total share capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement. Diluted share / voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities / warrants into equity shares of the TC.